## 10/584345 iAP20 Rec'd PCT/PTO 23 JUN 2006

Atty. Dkt. No. 081356-0262

### IN THE UNITED STATES PATENT AN D TRADEMARK OFFICE

Applicant:

Nobuaki TAKAHASHI et al.

Title:

**MUTANTS OF ANTI-CD40 ANTIBODY** 

Int'l. Appl. No.:

PCT/JP2004/019750

Int'l. Filing

12/24/2004

Date:

Unassigned

Art Unit:

Examiner:

Unassigned

Confirmation

Unassigned

Number:

### UNDER 37 CFR §1.56

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

Atty. Dkt. No. 081356-0262

## TIMING OF THE DISCLOSURE REC'D PCT/PTO 23 JUN 2006

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the filing date of the application.

### RELEVANCE OF EACH DOCUMENT

The documents being cited in the attached PTO/SB/08 were cited as being relevant during the prosecution of the corresponding international application. A copy of the International Search Report is attached setting forth the portion of the documents considered relevant by the examiner. A copy of the cited references listed in the Search Report are not being submitted herewith.

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

FOLEY & LARDNER LLP

Customer Number: 22428

Telephone: Facsimile:

(202) 672-5404 (202) 672-5399 Courtegay C. Brinckerhoff

Attorney for Applicant Registration No. 37,288

# IAP20 Rec'á PCT/PTO 23 JUN 2006 MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Pap	erwork Reduction Act of 199	95, no pers	ons are required t	o respond to a collection of information unless i	t contains a valid OMB control number.					
	Substitute for form	n 1449B/P	го	Complete if Known						
	INFORMATION D	DISCLOS	JRE	Application Number	Unassigned 112042	42				
	STATEMENT BY	APPLICA	ANT	Filing Date	June 23, 2006	-				
	Date Submitted:	luno 23 -2	2006	First Named Inventor	Nobuaki TAKAHASHI					
	Date Submitted.	Julie 25, 2	.000	Group Art Unit	Unassigned					
	(use as many sheet	ts as nece	ssary)	Examiner Name	Unassigned					
Sheet	1	of	2	Attorney Docket Number	081356-0262					

U.S. PATENT DOCUMENTS								
Examiner Initials*	Cite	U.S. Patent Document		Name of Patentee or Applicant of Cited	Date of Publication of	Pages, Columns, Lines, Where Relevant		
	No.1	Number	Kind Code <sup>2</sup> (if known)	Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear		
			-					

						FOREIGN PATENT DOCUMENTS	S		
Examiner Initials*	Cite No.1		ign Patent Doo Number <sup>4</sup>	cument Kind Cod	-	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Le
		WO 2	2002/088186		A1	Kirin Brewery Co., Ltd.	11/7/2202		
		JP 20	003-519470		A	SEATTLE GENETICS INC.	6/24/2003		
-									

•		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	Te
		E.E. IDUSOGIE et al., "Mapping of the Clq binding site on rituxan, a chimeric antibody with a human IgGI Fc", 2000, J. Immunol., 164(8), p. 4178-4184.	
,		M. H. TAO et al., "Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation", 1993, J. Exp. Med., 178(2), pp. 661-667.	
		A. MORGAN et al., "The N-terminal end of the CH2 domain of chimeric human IgGI anti-HLA-DR is necessary for Clq, Fc gamma RI and Fc gamma RIII binding", 1995, Immunology, 86(2), pp. 319-324.	
		M. P. REDDY, et al., "Elimination of Fc Receptor-Dependent Effector Functions of a Modified IgG4 Monoclonal Antibody to Human CD4", 2000, J. Immunol., 164, pp. 1925-1933.	
		S. ANGAL et al., "A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody", 1993, Mol. Immunol. 30(1), pp. 105-108.	

Examiner Signature	Date Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

iAP20 Rec'd PCT/PTO 2030 IF IN 1973 (2002). OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Pap	elwork Reduction Act (	n 1995, no peis	ons are required t	o respond to a collection of information diffess	it contains a valid Owlb control rightber.				_
	Substitute fo	r form 1449B/P	то		Complete if Known 🙀 🎧	1	O la	7	JI E
	INFORMATI	ON DISCLOS	URE	Application Number	Unassigned 🍩 🐸 🍍	-	777		7
	STATEMEN	T BY APPLIC	ANT	Filing Date	June 23, 2006				
	Data Cubmit	ted: June 23, 2	onne	First Named Inventor	Nobuaki TAKAHASHI				
	Date Submit	ied. June 25, 2	2000	Group Art Unit	Unassigned				
	(use as many s	sheets as nece	essary)	Examiner Name	Unassigned				
Sheet	2	of	2	Attorney Docket Number	081356-0262				

		NON PATENT LITERATURE DOCUMENTS									
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.									
-2. 3		Y. XU et al., "Residue at position 331 in the IgGI and IgG4 CH2 domains contributes to their differential ability to bind and activate complement", 1994, J. Biol. Chem. 269(5), pp. 3469-3474.									
and the second second		M. H. TAO et al., "The differential ability of human IgGI and IgG4 to activate complement is determined by the COOH-terminal sequence of the CH2 domain", 1991, J. Exp. Med., 173(4), pp. 1025-1028.									
		E.E. IDUSOGIE et al., "Engineered antibodies with increased activity to recruit complement", 2001, J. Immunol., 166(4), pp. 2571-2575.									
		R.C. AALBERSE et al., *IgG4 breaking the rules*, 2002, Immunology 105(1), pp. 9-19.									
<u> </u>		R. NEWMAN et al., "Modification of the Fc Region of a Primatized IgG Antibody to Human CD4 Retains Its Ability to Modulate CD4 Receptors but Does Not Deplete CD4+ T Cells in Chimpanzees", 2001, Clinical Immunology, 98(2), pp. 164-174.									
. 7,											
		·									
		,									

Examiner Signature	Date Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2See attached Kinds of U.S. Patent Documents. 3Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 

Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 

Applicant is to place a check mark here if English language Translation is attached.